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Abstract
Background: High plasma viremia in HIV-1 infection is associated with rapid CD4 cell decline and faster disease
progression. Children with HIV infection have high viral loads, particularly in early childhood. In this study we
sought to understand the relationship between duration of HIV-1 infection and viral dynamics among
perinatally-infected children and adolescents in India along with transmitted drug resistance in this population.
Methods: During 2007–2011, cross-sectional samples were collected from ART-naïve children (n = 105) with
perinatally-acquired HIV infection, aged 2–16 years from Bangalore, India. CD4 counts, viral load and in-house
genotyping were performed and transmitted drug resistance mutations were identified using the World Health
Organization recommendations for Surveillance of Drug Resistance Mutations (SDRM_2009) list.
Results: Among 105 children studied, 73.3% (77/105) were asymptomatic, but had a median viral load of 5.24 log
copies/mL (IQR 4.62-5.66). In the adolescent age group, 54% (21/39) had high levels of viremia (median 5.14 log
copies/mL) but were asymptomatic. HIV-1 subtyping identified 98% strains (103/105) as subtype C; one A1 and one
unique recombinant form (URF). Transmitted NRTI resistance was 1.9% (2/105); NNRTI resistance was 4.8% (5/105)
and overall prevalence of transmitted drug resistance was 5.7% (6/105).
Conclusions: The high burden of plasma viremia found among untreated asymptomatic adolescents needs to be
addressed both from an individual angle to halt disease progression, and from a public health perspective to arrest
horizontal transmission. The low level of transmitted drug resistance among perinatally-infected children is
reassuring; however with improving ART access globally, regular genotyping surveillance is indicated.
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Background
Globally, 3.4 million children below 15 years of age are
living with HIV as of 2010 (World Health Organisation,
Global summary of the AIDS epidemic, 2010). Among
them 1.4 million children reside in the South-east Asia
region alone. India has a burden of nearly 2.5 million
HIV-1 infected individuals, with children below 15 years
of age constituting 3.5% of the total number [1].
Viral load dynamics occurring immediately after infec-
tion has been well characterized in adults [2]. Perinatal
infection has differing post-transmission dynamics, and
consists of a rapid rise in the viral load up to 105 to 107
copies/ml during the first weeks of life followed by a de-
clining trend up to 5 to 6 years [3-5]. Extracellular viral
load is a strong indicator of viral replication and high
viremia is associated with high transmissibility of HIV-1
[6-8]. Although HIV-1 subtype C infection accounts for
nearly half (48%) of global HIV infections, few studies
have focussed on subtype C viral dynamics. High viremia
is seen in a substantial proportion of adults with HIV-1
subtype C infection acquired via horizontal transmission
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[8,9]. Specific data on viral dynamics among perinatally-
infected children are limited [3] and have not been stud-
ied within the context of HIV-1 subtype C infection.
Transmitted drug resistance mutation (TDRM) sur-
veillance in children can help to enhance our under-
standing of transmission of specific clinically-relevant
mutations in the era of rapid scale-up of free antiretro-
viral therapy, particularly prevention of mother-to-child
transmission measures. In India, although few studies
have previously addressed prevalence of TDRM in
adults, [10-12] limited information is available for chil-
dren and adolescents. The present study aims to under-
stand the relationship between the duration of HIV-1
infection and viremia in children in a setting of HIV-1
subtype C dominance. In addition, the study reports the
prevalence of transmitted drug resistant mutations
among ART-naive perinatally-infected children.
Methods
Study population
The study participants included all children with HIV-1
infection who were regularly visiting the Infectious Dis-
ease Clinic at a tertiary care hospital, St. John’s Medical
College and Hospital, Bangalore, India since March
2007. Among these, 105 children aged between 2 to
16 years who were perinatally infected, ART-naïve, and
with no antenatal exposure to ART, were included in
this analysis.
Perinatal infection was confirmed by documented evi-
dence that the mother or both parents were HIV-
infected. There was no history of blood transfusion,
cross-breast feeding or sexual abuse/exposure among
the children included in the study. All the children were
therapy-naïve and were diagnosed in early or middle
childhood at an average age of 6 years. Maternal HIV
status was unknown at the time of birth of these chil-
dren but was confirmed subsequently, and none of the
mothers had received prophylactic antiretroviral drugs
during the antenatal period.
Viral Load, PCR and sequencing
Between 2007 and 2011, a single peripheral blood sam-
ple was obtained from each study subject during a rou-
tine follow up visit in the clinic. Given that the children
in the study were confirmed to be perinatally infected,
the duration of HIV infection at the time of sample draw
in these children was known. Plasma was separated out
after centrifugation and stored at −80 °C until used.
Viral load was measured by real time polymerase chain
reaction using the Abbott m2000rt system (Abbott Mo-
lecular Diagnostics, Germany). Routine CD4 count was
measured with Dual-platform flow cytometer (FACS
Calibur, BD, USA). PCR and sequencing was carried out
as described by us previously [10]. In brief, viral RNA
was extracted from plasma using a commercial kit
(QIAamp Viral RNA extraction kit, Qiagen, Germany).
Partial RT, HXB2 position 2598 to 3250 (corresponds
to 17–235 amino acid) regions of the polymerase (pol)
gene were amplified using reverse transcriptase poly-
merase chain reactions (RT-PCR) followed by conven-
tional nested PCR using the following primers, RT04
50-CCTATTGAAACTGTACCAGT-30 and RT05,50-AC
TGTCCATTTATCAGGATG-30 followed by RT07 50
AAGCCAGGAATGGATGGCCCA-30 and RT06 50-CC
ATTTATCAGGATGGAGTTC-30. The purified PCR
products were subjected to bidirectional population se-
quencing using RT06 and RT07 primers in 3730xl
DNA analyzer (Applied Biosystems, CA, USA) using
the second round primers. A consensus sequence was
created using BioEdit sequence alignment editor version
7.0.5.3 [13].
Quality control
An external quality control program by the Quality Con-
trol for Molecular Diagnostics, Glasgow, Scotland
(QCMD, www.qcmd.gov) was maintained by the labora-
tory where these analyses were performed.
Reference sequences
Reference sequences (2010) of different subtypes (n = 170)
were downloaded from HIV-1 Los Alamos Database
(“LANL”, www.hiv.lanl.gov). The reverse transcriptase
(RT) sequences of previously reported sequences from
India, obtained from patients where the therapy status
was documented, were downloaded from the same data-
base. A total 595 RT sequences from therapy-naïve patients
were downloaded from the LANL database reported in
previous studies from India [10-12,14-19]. The downloaded
sequences were assessed for accuracy by using the Los
Alamos Quality Control tool (LANL_QC) for HIV-1
sequences. Using this tool, sequences with frame shifts,
≥3 stop codons, and APOBEC-mediated hypermutations
were excluded, leaving the remaining 567 unique and
correctly aligned sequences for the final analysis.
Phylogenetic analysis, subtyping and recombinant
screening
Subtyping was inferred using a maximum likelihood
(ML) phylogenetic tree constructed with 1000 boot-
strapped data sets, using the Molecular Evolutionary
Genetics Analysis software version 5 (MEGA 5) with the
subtype reference sequences downloaded from the data-
base [20]. All sequences were further submitted to Re-
combination Identification Program 3.0 (RIP 3.0). The
sequences which showed recombination were further
processed for detailed analysis of recombination break-
points. Recombination patterns were determined by per-
forming bootscan analysis with Simplot version 3.5.1
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[21], using a window sliding of 100 nucleotide (nt) in
10nt steps, with 500 bootstrap replicates. The mosaic
pattern of each URF was confirmed by phylogenetic ana-
lysis of the recombination fragments using the same
parameters as described above.
Drug resistance genotyping and definition of transmitted
drug resistance mutations
Genotyping was performed on plasma samples derived
from ART-naïve children. Briefly, the reverse transcript-
ase (RT) region of HIV-1 pol gene was amplified and
sequenced using the primers described above. These
sequences were analysed for the presence of transmitted
drug resistance using the World Health Organization
(WHO) recommendations for surveillance of drug resist-
ance mutations updated in 2009 (SDRM_2009) [22].
This list includes 34 NRTI-resistance mutations at 15 RT
positions, and 19 NNRTI-resistance mutations at 10 RT
positions [22]. We also used the International AIDS
Society-USA updated drug resistance mutations in HIV-1
(IAS-USA 2011) for interpretation of TDRM. IAS-USA
2011 includes 19 NRTI mutations in 16 positions, and 34
NNRTI mutations in 16 positions between amino acid
residues 17 to 235 of RT region of pol [23]. To further
increase the accuracy of this analyses, we eliminated
certain mutations included in the SDRM_2009 or IAS
Panel, which displayed characteristics of polymorphisms
(defined as those mutations which are normally present
at a frequency of ≥0.5% in therapy-naïve patients, and
at a frequency of <0.5% among those failing therapy)
[22].
Intra-population divergence
The genetic distance of each of the study sequences to
the Indian consensus C sequence (intra-population di-
vergence) was calculated in MEGA 5 software [20].
Statistical methods
Descriptive statistics like mean, median were calculated
in SPSS ver 16.0. A spearman rank co-relation (rs) was
used for analysis of potential co-relation between con-
tinuous variables. P value <0.05 was considered as
significant.
Ethical statement
The study has been approved by institutional ethical re-
view board, St. John’s Medical College Hospital, Banga-
lore, India. Written informed consent was obtained from
all caregivers prior to recruitment of the children, and a




Among the total of 105 children studied, mean age was
8 years (SD ± 3.4) and median CD4 count was 530 cells/
mm3 (IQR 338, 780) (Table 1). Median viral load was
5.24 log copies/mL (IQR 4.62, 5.66) and 73.3% of these
children (77/105) were classified as clinically stable
(WHO clinical stage I or II) and remaining 28 children
were classified as symptomatic (WHO clinical stage III
or IV). As perinatal infection was the most likely mode
of transmission, the duration of infection was deemed to
be equivalent to the age of each child.
Extended high viremia and CD4 count
Viral load values remained similar regardless of age, and
showed no significant correlation with duration of infec-
tion in these populations (Figure 1). CD4 T-cell count
weakly correlated with viral load among children ≥5 years
of age (n = 88; Spearman rho = −0.26). Among these 88
children, 58% (51/88) were extended high viremics (>5.0
log copies/mL as described previously [8]) and among
these, 67% (34/51) had CD4 count higher than 350 cells/
mm3. In the adolescent age group (10–16 years of age,
n = 39), 54% (21/39) had extended high viremia (median
5.14 log copies/mL; IQR 4.69-5.34) despite having a CD4
T-cell counts >350 cells/mm3.
HIV-1 subtyping
HIV-1 subtyping based on RT region of pol gene (HXB2
position 2598 to 3250) identified 98% strains (103/105)
as subtype C which is predominant in India [24] (Figure 2).
One sample was identified as subtype A1 and one as
a unique recombinant form CH (URF_CH). (Figure 3).
Transmitted drug resistance and polymorphisms
Using the SDRM_2009 list [22] for drug resistance
monitoring, we found that among the 105 ART-naïve
children, 3.8% (4/105) had transmitted NRTI drug re-
sistance mutations (L74I, T69D, T215S and K219Q)
and 4.8% (5/105) had NNRTI drug resistance muta-
tions [K103N (n = 2), K101E (n = 2), Y181C (n = 1)].
After excluding likely polymorphisms such as L74I and
T215S, transmitted NRTI resistance prevalence was
1.9% (2/105). The overall prevalence of transmitted
drug resistance in this population was 5.7% (6/105).
Among the six strains, only one had two classes of
mutations (both NRTI and NNRTI) (Table 2).
When the IAS-USA 2011 list [23] was used for TDRM
interpretation, a slightly differing result was obtained.
The NRTI resistance prevalence was 0.9% (1/105;
K219Q) and NNRTI resistance was 5.7% [6/105; K103N
(n = 2), K101E (n = 2), Y181C (n = 1), F227C (n = 1)]. But
the overall transmitted drug resistance prevalence
remained the same; 5.7% (6/105).
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The profiles of children with transmitted drug resist-
ance are presented in Table 2. Children who had TDRM
(n = 6), had higher mean viral load compared to those
with no TDRM (n = 99) (5.75 vs 5.16 log copies/mL; p =
0.06) although only a trend towards significance was
seen due to the small sample size. Among the six chil-
dren who had TDRM, 3 children had severe immuno-
suppression and were deemed eligible to start ART.
Discussion
Our study on viral dynamics and drug resistance testing
among ART-naive perinatally-infected children aged be-
tween 2 and 16 years found that a substantial proportion
of older children with CD4 T cell count in the ‘non-
immunosuppressed’ category had high viremia. As
expected subtype C is the most prevalent HIV-1 subtype
in this study population. We also identified a low level
of transmitted drug resistance in this population.
A recent study showed that a proportion of HIV-
infected adults with horizontally-acquired subtype C in-
fection in southern Africa maintained high viral loads
for a prolonged period of time [8]. A South African co-
hort of HIV-1-infected infants also demonstrated high
viral load where HIV-1 subtype C is predominant [25].
A comparative study between Malawi and US/Swiss
study participants also showed a significant higher viral
load in Malawians, suggesting the possibility that high
viremia may occur more frequently in subtype C rather
than subtype B infection [9]. In our cohort, the duration
of infection as measured by the age of these children,
did not directly correlate with the degree of viremia,
thus precluding viral load measurement as a prognostic
marker of disease length; moreover, there was a sub-
stantial proportion of adolescents who maintained high
CD4 T-cell count but had elevated viremia as well.
Our findings imply that even in vertical transmission, a
proportion of HIV-1 subtype C-infected children and
adolescents have high viremia irrespective of their stable
clinical and immunological status. To minimize horizon-
tal transmission among youth, targeted interventions
with treatment as prevention among adolescents with
high viremia may be of public health benefit which could
also be a cost-effective strategy to attain maximum
population-level reductions in HIV-1 transmission [26].
The transmitted drug resistance prevalence was
derived by using the SDRM 2009 list [22]. The SDRM
2009 list was compiled keeping in mind four main con-
cepts: (i) included mutations should be recognized as
causing or contributing to drug resistance - by being
present on ≥3 of five existing expert lists of drug resist-
ance mutations, namely, Stanford university HIVdb
drug resistance interpretation algorithm (http://hivdb.
stanford.edu/). IAS-USA Mutations Associated With
Drug Resistance (March/April 2008), ANRS drug resist-
ance interpretation algorithm, Los Alamos National









Sex: Male (%) 61 (58.1%) 12 (70%) 29 (59%) 20(51%)
CD4-T cell count 530 (338–780) 1051 (528–1154) 586 (401–768) 373 (251–578)
Median (IQR*)
Viral load log copies/mL 5.24 (4.62-5.66) 5.56 (5.51-6.05) 5.12 (4.55-5.55) 5.2 (4.73-5.63)
Median (IQR*)
WHO Clinical stage
Stage 1 40 (38.1%) 6 (35.3%) 19 (38.7%) 15 (38.5%)
Stage 2 37 (35.2%) 5 (29.4%) 19 (38.7%) 13 (33.3%)
Stage 3 22 (21%) 4 (23.5%) 9 (18.4%) 9 (23.1%)
Stage 4 6 (5.7%) 2 (11.8%) 02 (4.1%) 2 (5.1%)
*IQR: Inter-quartile range.
Figure 1 Association between duration of infection and log
transformed viral load. The graph represents association between
log transformed viral load and length of the infection in perinatal
transmission. No significant correlation between the parameters
observed (Spearman rho = −0.189; p = 0.05).
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Laboratories HIV Sequence database (2007), or Rega In-
stitute Drug Resistance Interpretation Algorithm (7.1.1)
(ii) the mutations should not be polymorphisms or occur
at highly polymorphic positions, (iii) the mutations
should be applicable to the 8 most common HIV-1 sub-
types globally and (iv) the list should be parsimonious,
excluding mutations that are unlikely to result from drug
pressure. These criteria have shaped the SDRM 2009 list
to be especially relevant in our setting, and hence this
list was used for our current interpretation. The TDRM
level in our study population was very low which was
consistent with our previous findings where the level of
TDRMS and polymorphisms among ART-naïve adults
did not exceed 10% [10]. Other paediatric studies from
India have revealed similar low TDRM prevalence;
among a south Indian cohort of 48 perinatally infected
children of mean age 5.7 years, none had major drug re-
sistance mutations [27]. In another study from north
India where 25 ART-naïve children with mean age
6 years were studied, K103N was the only drug resist-
ance mutation that was observed [28]. Studies on ART-
naïve adults from different parts of India with sample
sizes ranging from 34 to 107 patients, have revealed low
TDRM prevalence (<5%) [11,12,14-18].
Figure 2 Identification and characterisation of HIV-1 subtypes. The tree was constructed with cohort sequences and reference sequences
downloaded from Los Alamos Database (www.hiv.lanl.gov) using general time reversible (GTR) model with gamma distribution and invariant sites
(GTR + G + I) as observed best fitted model for the dataset. Cohort sequences are shown with filled circle.
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Figure 3 Mosaic structure of identified unique recombinant forms (URF) strains. The strain, which was determined as URF_CH in RIP 3.0
program was further studied in details for its mosaic structure. The recombination patterns were determined by performing bootscan analysis
with Simplot version 3.5.1 [21], using a window sliding of 100 nucleotide (nt) in 10nt steps, with 500 bootstrap replicates. The informative sites
were presented inside the graph. The mosaic pattern of each segments were confirmed by phylogenetic analysis using reference subtype C and
H strains downloaded from Los Alamos Database (www.hiv.lanl.gov). Two breakpoints were identified at 2816 and 2911 of HXB2 co-ordinates.
Table 2 Profile of children with transmitted drug resistance
Patient No Length of infection (years) WHO Stage CD4 Count (cells/mm3) Viral Load (log copies/mL) NRTI SDRMs NNRTI SDRMs
1 16 3 221 6.46 None K103N
2 11 3 417 5.34 None K101E
3 11 4 14 5.69 T69D None
4 9 1 247 5.08 None K103N
5 9 1 401 5.50 K219Q K101E
6 6 2 288 6.55 None Y181C
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Presence of K103N and K101E TDRM in our cohort
sequences may be due to wide usage of nevirapine in
this setting [29]. Our data on prevalence of TDRM
among children was significantly lower than other set-
tings. Studies from Brazil reported 26.9% of TDRM in
therapy-naïve children [30], while a report from Central
African Republic identified 13.9% [31]. A meta-analysis
showed that approximately half of the children with
PMTCT exposure (single-dose nevirapine) harboured
TDRM [32]. A recent study from Spain on PMTCT-
exposed children identified 13% TDR [33], while another
study from Western Cape Province of South Africa
reported TDRM <5% among children who were exposed
to PMTCT [34]. A recent study also showed that the ef-
fect of viral fitness on HIV RNA level could be one of
the determining factors for selective viral transmission;
maternal presence of mutations such as K103N which
promote viral fitness may be easily transmitted to infants
[35].
Minor differences between the two lists used for
TDRM interpretation can lead to contradictory preva-
lence results of drug resistance. In our study, we
excluded minor NRTI mutations such as T215S and
L74I which were included in the SDRM 2009 list. The
SDRM 2009 WHO group recommends that the SDRM
list should be “as parsimonious as possible without sacri-
ficing sensitivity,” this can be accomplished by excluding
“exceedingly rare drug-resistance mutations defined as
those mutations present at a frequency below 0.5%
among treated individuals in the subtype having the
highest prevalence of that mutation” [22]. Our analysis
of previous RT sequences obtained from treatment-
experienced patients from Indian subtype C patients [n =
606; downloaded from the Los Alamos database (n =
102); literature survey (n = 446) and unpublished from lab
(n = 58)] revealed that T215S was not present in any of
the sequences (data not shown). Although in vitro ana-
lysis showed that T215S represents revertants of T215Y
[36], phenotypic characterisation did not show resistance
to any nucleoside analogues including zidovudine [37].
The L74I mutation was present in 0.3% (2/606) of
sequences obtained from treatment-experienced patients
infected with subtype C viruses. In addition, the analysis
of global subtype C sequences in HIVseq program avail-
able in Stanford University HIV drug resistance database
(http://hivdb.stanford.edu/; accessed 07 October 2012)
also revealed absence of both mutations in 232 HIV-1
subtype C sequences from NRTI-treated patients. The
low prevalence of T215S and L74I at a frequency of
<0.5% in treatment-experienced patients harbouring
subtype C HIV-1 provided the basis for our rationale for
excluding these mutations from our analysis. F227C is
another example of a mutation included in the IAS-USA
panel that is not likely to be significant as a transmitted
mutation, as F227C confers “minor” resistance to rilpivir-
ine, a drug that is as yet unavailable in India. Other
studies have observed differences in prevalence of TDRM
within the same cohort when differing tools such as
SDRM 2009 and IAS-USA 2009 are used [38]. Current
SDRM 2009 guidelines propose that such polymorphic
drug resistance mutations which occur commonly in the
absence of drug selective pressure, and are present
in <0.5% of the treated population, could lead to falsely
elevated estimates of TDRM, and hence, must not be
included for surveillance of transmitted HIVDR [22].
Our study limitations include the cross-sectional de-
sign which restricts our ability to comment on kinetics
of viral dynamics and evolution. Further, we have not
been able to include samples from children below two
years of age for this analysis as most of the children in
our settings were diagnosed in their early and middle
childhood. There may be an inherent survival bias since
only these older children were included in the study.
Thus, having only chronically infected children may ac-
tually underestimate the prevalence of transmitted drug
resistance as the wild type virus with increased fitness
may predominate and minor viral populations with drug
resistant mutations may be too low to detect using
population sequencing. However, our study is strength-
ened by the inclusion of a high proportion of children
with age ≥10 years, which allowed us to study viral
load and its associations in adolescents. Finally, the
population-based genotyping method can only detect
mutations that are present in 30% or more of the
quasi-species constituting circulating virus population
[39]. It is possible that mutations carried by minor
viral populations may be missed due to the limited
sensitivity of population-based sequencing method.
Conclusions
Our study is the first of its kind which describes the
relationship between the length of infection and the
degree of viremia in perinatally-infected children and
adolescents living with HIV-1 subtype C in India.
A significant finding of this study is the inconsistent
clinical parameters of high viral load and high CD4
count co-existing in over half the adolescents studied,
where the duration of infection is >10 years. Studies
have shown a high probability of disease progression to
AIDS among those with high viremia [40]. Will this
group of adolescent extended high viremics experience
imminent rapid disease progression as has been seen in
adult studies? It is conceivable that extended high
viremia with drug resistance mutations in untreated
adolescents may also play a role in fuelling the HIV
epidemic. Therefore, early initiations of ART while
emphasizing good adherence may be considered in this
population in order to attain maximum population-level
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reductions in HIV-1 transmission. The evidence from
this study also suggests that the interpretation of preva-
lence of TDRM in population-based surveillance should
be used with caution to avoid reporting falsely elevated
TDR prevalence in the population. The low level of
transmitted drug resistance in children unexposed to
antenatal antiretroviral drugs, although reassuring,
should not advocate complacency. Regular surveillance
is necessary to understand the evolution of drug resist-
ance mutations, particularly with increasing PMTCT
coverage nationally and globally.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
UN conceived of the study, and participated in its design, carried out the
drug resistance genotyping, bioinformatics analysis, performed the statistical
analysis and drafted the manuscript. PNS carried out the lab works, helped in
clinical data accumulations. ADC performed the statistical analysis, inputs in
the public health aspects and critically reviewed the manuscript. AS
conceived of the study, and participated in its design and critically reviewed
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank the staff of the Pediatric Infectious Disease Clinic, St. John’s
Hospital, Bangalore, and Sneha Care Home for assistance with patient
recruitment. A special thanks to Shwetha D Rao, for helping in the data
collection. We would also like to thank the National AIDS Control
Organisation (NACO), Government of India, for their support and care of
these children. Most importantly, we are ever grateful to the children for
participating in this study and giving so much to help us learn.
Funding
The study was partly funded by the Child Health Foundation, the
International Nutrition Foundation, the Indian Council of Medical Research,
and the European Union FP7 grant.
Author details
1Division of Infectious Disease, Department of Medicine, Huddinge,
Karolinska Institutet, Stockholm, Sweden. 2Division of Clinical Virology,
Department of Microbiology, St. John’s National Academy of Health Sciences,
Bangalore, India. 3Division of Global Health, Karolinska Institutet, Stockholm,
Sweden. 4Department of Paediatrics, St. John’s National Academy of Health
Sciences, Bangalore 560034, India.
Received: 6 June 2012 Accepted: 20 November 2012
Published: 22 November 2012
References
1. National AIDS Control Organization, Annual Report, 2009–2010. http://
nacoonline.org/upload/AR%202009-10/NACO_AR_English%20corrected.pdf.
2. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D,
Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI:
Consistent viral evolutionary changes associated with the progression of
human immunodeficiency virus type 1 infection. J Virol 1999,
73:10489–10502.
3. Ganeshan S, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM: Human
immunodeficiency virus type 1 genetic evolution in children with
different rates of development of disease. J Virol 1997, 71:663–677.
4. McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, Burchett
SK: Age- and time-related changes in extracellular viral load in children
vertically infected by human immunodeficiency virus. Pediatr Infect Dis J
1996, 15:1087–1091.
5. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, Rich K,
Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA: Viral load and
disease progression in infants infected with human immunodeficiency
virus type 1. Women and Infants Transmission Study Group. N Engl J Med
1997, 336:1337–1342.
6. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen
F, Meehan MO, Lutalo T, Gray RH: Viral load and heterosexual
transmission of human immunodeficiency virus type 1. Rakai Project
Study Group. N Engl J Med 2000, 342:921–929.
7. Modjarrad K, Chamot E, Vermund SH: Impact of small reductions in
plasma HIV RNA levels on the risk of heterosexual transmission and
disease progression. AIDS 2008, 22:2179–2185.
8. Novitsky V, Ndung’u T, Wang R, Bussmann H, Chonco F, Makhema J,
DeGruttola V, Walker BD, Essex M: Extended high viremics: a substantial
fraction of individuals maintain high plasma viral RNA levels after acute
HIV-1 subtype C infection. AIDS 2011, 25:1515–1522.
9. Dyer JR, Kazembe P, Vernazza PL, Gilliam BL, Maida M, Zimba D, Hoffman IF,
Royce RA, Schock JL, Fiscus SA, Cohen MS, Eron JJ Jr: High levels of human
immunodeficiency virus type 1 in blood and semen of seropositive men
in sub-Saharan Africa. J Infect Dis 1998, 177:1742–1746.
10. Neogi U, Prarthana BS, Gupta S, D’souza G, De Costa A, Kuttiatt VS,
Arumugam K, Shet A: Naturally occurring polymorphisms and primary
drug resistance profile among antiretroviral-naïve individuals in
Bangalore, India. AIDS Res Hum Retroviruses 2010, 26:1097–1101.
11. Thorat SR, Chaturbhuj DN, Hingankar NK, Chandrasekhar V, Koppada R,
Datkar SR, Srikantiah P, Garg R, Kabra S, Haldar P, Reddy DC, Bachani D,
Tripathy SP, Paranjape RS: Surveillance of transmitted HIV type 1 drug
resistance among HIV type 1-positive women attending an antenatal
clinic in Kakinada, India. AIDS Res Hum Retroviruses 2011, 27:1291–1297.
12. Chaturbhuj DN, Hingankar NK, Srikantiah P, Garg R, Kabra S, Deshmukh PS,
Jadhav SD, Thorat SR, Datkar SR, Mehta P, Ingole N, Mathur M,
Ramachandran A, Haldar P, Reddy DC, Bachani D, Rao S, Tripathy SP,
Paranjape RS: Transmitted HIV drug resistance among HIV-infected
voluntary counselling and testing centers (VCTC) clients in Mumbai,
India. AIDS Res Hum Retroviruses 2010, 26:927–932.
13. Hall TA: BioEdit: A user-friendly biological sequence alignment editor and
analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999,
41:95–98.
14. Sinha S, Ahmad H, Shekhar RC, Kumar N, Dar L, Samantaray JC, Sharma SK,
Bhargava A, Pandey RM, Mitsuyasu RL, Fahey JL: Prevalence of HIV drug
resistance mutations in HIV type 1 isolates in antiretroviral therapy
naïve population from northern India. AIDS Res Treat 2012,
2012:905823.
15. Deshpande A, Karki S, Recordon-Pinson P, Flury HJ: Drug resistance
mutations in HIV type 1 isolates from naive patients eligible for first line
antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum
Retroviruses 2011, 27:1345–1347.
16. Iqbal HS, Solomon SS, Madhavan V, Solomon S, Balakrishnan P: Primary
HIV-1 drug resistance and polymorphic patterns among injecting drug
users (IDUs) in Chennai, Southern India. J Int Assoc Physicians AIDS Care
(Chic) 2009, 8:323–327.
17. Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S: Antiretroviral
drug-resistant mutations at baseline and at time of failure of
antiretroviral therapy in HIV type 1-coinfected TB patients. AIDS Res Hum
Retroviruses 2009, 25:1179–1185.
18. Kandathil AJ, Kannangai R, Abraham OC, Rupali P, Pulimood SA, Verghese
VP, Grant P, Pillay D, Sridharan G: The frequency of HIV-I drug resistance
mutations among treatment-naive individuals at a tertiary care centre in
south India. Int J STD AIDS 2009, 20:522–526.
19. Balakrishnan P, Kumarasamy N, Kantor R, Solomon S, Vidya S, Mayer KH,
Newstein M, Thyagarajan SP, Katzenstein D, Ramratnam B: HIV type 1
genotypic variation in an antiretroviral treatment-naive population in
southern India. AIDS Res Hum Retroviruses 2005, 21:301–305.
20. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5:
Molecular Evolutionary Genetics Analysis using Maximum Likelihood,
Evolutionary Distance, and Maximum Parsimony Methods. Mol Biol Evol
2011, 28:2731–2739.
21. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG,
Ingersoll R, Sheppard HW, Ray SC: Full length human immunodeficiency
virus type 1 genomes from subtype C-infected seroconverters in
India, with evidence of intersubtype recombination. J Virol 1999,
73:152–160.
22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M,
Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom
Neogi et al. BMC Infectious Diseases 2012, 12:317 Page 8 of 9
http://www.biomedcentral.com/1471-2334/12/317
P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW:
Drug resistance mutations for surveillance of transmitted HIV-1
drug-resistance: 2009 update. PLoS ONE 2009, 4:e4724. doi:10.1371/journal.
pone.0004724.
23. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing
AM, Richman DD: 2011 update of the drug resistance mutations in HIV-1.
Top Antivir Med 2011, 19:156–164.
24. Neogi U, Bontell I, Shet A, De Costa A, Gupta S, Diwan V, Laishram RS,
Wanchu A, Ranga U, Banerjea AC, Sönnerborg A: Molecular epidemiology
of HIV-1 subtypes in India: Origin and evolutionary history of the
predominant subtype C. PLoS ONE 2012, 7(6):e39819.
25. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe
P, McIntyre JA, CHER Study Team: Early antiretroviral therapy and
mortality among HIV-infected infants. N Engl J Med 2008, 359:2233–2244.
26. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J,
Lingappa JR, Celum C, Partners in Prevention HSV/HIV Transmission Study
Team: Heterosexual HIV-1 transmission after initiation of antiretroviral
therapy: a prospective cohort analysis. Lancet 2010, 375:2092–2098.
27. Soundararajan L, Karunaianandham R, Jauvin V, Schrive MH, Ramachandran
R, Narayanan PR, Fleury HJ, Swaminathan S: Characterization of HIV-1
isolates from antiretroviral drug-naive children in southern India.
AIDS Res Hum Retroviruses 2007, 23:1119–1126.
28. Sehgal S, Pasricha N, Singh S: High rate of mutation K103N causing
resistance to nevirapine in Indian children with acquired
immunodeficiency syndrome. Ind J Med Microbiol 2008, 26:372–374.
29. Neogi U, Shet A, Shamsundar R, Ekstrand ML: Selection of nonnucleoside
reverse transcriptase inhibitor-associated mutations in HIV-1
subtype C: evidence of etravirine cross-resistance. AIDS 2011,
25:1123–1126.
30. Pedrosa C, Queiroz AT, Alcantara LC, Drexler JF, Diaz RS, Weyll N, Brites C:
High prevalence of primary antiretroviral resistance among HIV-1
infected adults and children in Bahia, a northeast state of Brazil.
J Acquir immune Defic Syndr 2007, 45:251–253.
31. Charpentier C, Gody JC, Tisserand P, Matta M, Péré H, Fournier J, Mbitikon
O, Bélec L: Surveillance of antiretroviral drug resistance mutations in
untreated young children living in the Central African Republic.
Antivir Ther 2011, 16:1347–1350.
32. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy
V, Perre PV, Rouzioux C, Dabis F, Ghent Group on HIV in Women and
Children: Prevalence of resistance to nevirapine in mothers and children
after single-dose exposure to prevent vertical transmission of HIV-1: a
meta-analysis. Int J Epidemiol 2007, 36:1009–1021.
33. De Mulder M, Yebra G, Martin L, Prieto L, Mellado MJ, Rojo P, Muñoz-
Fernández MÁ, Jiménez de Ory S, Ramos JT, Holguín A, Madrid cohort of
HIV-infected children: Drug resistance prevalence and HIV-1 variant
characterization in the naïve and pretreated HIV-1- infected paediatric
population in Madrid, Spain. J Antimicrob Chemother 2011,
66:2362–2371.
34. van Zyl GU, Cotton MF, Claassen M, Abrahams C, Preiser W: Surveillance of
transmitted resistance to antiretroviral drug classes among young
children in the Western Cape Province of South Africa. Pediatr Infect Dis J
2010, 29:370–371.
35. Poon AFY, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez
B, Boswell SL, Frost SD, Haubrich RH: Transmitted Drug Resistance in the
CFAR Network of Integrated Clinical Systems Cohort: Prevalence and
Effects on Pre-Therapy CD4 and Viral Load. PLoS ONE 2011, 6:e21189.
doi:10.1371/journal.pone.0021189.
36. de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E,
van Gemen B, de Boer R, Goudsmit J: Establishment of new transmissible
and drug-sensitive human immunodeficiency virus type 1 wild types
due to transmission of nucleoside analogue-resistant virus. J Virol 2001,
75:595–602.
37. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W: Increased
ability for selection of zidovudine resistance in a distinct class of wild-
type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 2001,
98:13907–13912.
38. Sungkanuparph S, Kiertiburanakul S, Sukasem C, Chantratita W:
Discrepancies between WHO 2009 and IAS-USA 2009 lists for
determining the rate of transmitted HIV-1 drug resistance: a prospective
study. J Acquir Immune Defic Syndr 2012, 59:e3–e5.
39. Guidelines for surveillance of HIV drug resistance. 2003, http://wwwn.cdc.
gov/dls/ila/cd/who-afro/resisguide12_12.pdf.
40. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P,
Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr: Plasma viral
load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
Ann Intern Med 1997, 126:946–954.
doi:10.1186/1471-2334-12-317
Cite this article as: Neogi et al.: High viremia and low level of
transmitted drug resistance in anti-retroviral therapy-naïve perinatally-
infected children and adolescents with HIV-1 subtype C infection. BMC
Infectious Diseases 2012 12:317.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Neogi et al. BMC Infectious Diseases 2012, 12:317 Page 9 of 9
http://www.biomedcentral.com/1471-2334/12/317
